<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="Brazil is the most affected country to date ( WHO." exact="World Health Organization," post="2017). Since June 2015, we have been receiving samples"/>
 <result pre="Center for the Diagnosis of Emerging Viruses of the Brazilian" exact="Ministry of Health," post="we obtained the waiver for the written informed consent"/>
 <result pre="(from noninfected cells) cell cultures as antigens according to the" exact="Centers for Disease Control and Prevention" post="( CDC. Centers for Disease Control and Prevention, 2017)"/>
 <result pre="to the Centers for Disease Control and Prevention ( CDC." exact="Centers for Disease Control and Prevention," post="2017) guidelines, with minor modifications. A humanized anti-flavivirus monoclonal"/>
 <result pre="support. Financial support: Fiocruz, CNPq, Capes Zika Fast Track and" exact="Fundação Araucária." post="CNDS and LN have a CNPq fellowship. References ↵"/>
 <result pre="375, 2321– 2334. doi: 10.1056/NEJMoa1602412. OpenUrl CrossRef PubMed ↵ CDC." exact="Centers for Disease Control and Prevention" post="( 2017). Zika MAC-ELISA. Available at: http://www.cdc.gov/zika/pdfs/zika-mac-elisa-instructions-for-use.pdf [Accessed July"/>
 <result pre="syndrome. J AAPOS 21, 295– 299. OpenUrl PubMed ↵ WHO." exact="World Health Organization" post="( 2017). Zika situation report. 2017. Available at: http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf?ua=1"/>
</results>
